Current Treatment Landscape for KRASG12C-Mutated NSCLC

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.

In patients who were pretreated and treatment naïve with RET fusion-positive NSCLC, selpercatinib yielded an ORR of 61.5% and 82.6%, respectively.